OGEN
Oragenics Inc
$0.59
+0.01 (+1.72%)
At close · Jul 10
Market Cap
$2.64M
Shares
4,511,957
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.59
Open$0.58
Day$0.58–0.60
52W$0.50–1.49
Avg vol 30d47K
Short int775K · 17.2% float · 16.8d
Short vol86%
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
9%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−37%
trailing
YTD return
−24%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+17% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.18% of float · ▲ +3.0% MoM · 16.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
21 holders — near 1-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
−9%
Y/Y
Gross margin
0%
EPS growth
+90%
Y/Y
Free cash flow
$-9.4M
Balance sheet
$4.4M
net cash
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
9%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+17% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.18% of float · ▲ +3.0% MoM · 16.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
21 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 9%
52-wk high $1
vs 200-day avg -29%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OGEN
this stock
Oragenics Inc
|
$2.64M | -24.4% | -8.9% | — | 17.2% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OGEN | +0.0% | +0.0% | -37.2% | +1.7% | -24.4% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -1.4% | -4.1% | -46.3% | +0.6% | -35.1% |